vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and Foghorn Therapeutics Inc. (FHTX). Click either name above to swap in a different company.
Broadway Financial Corp is the larger business by last-quarter revenue ($9.4M vs $9.2M, roughly 1.0× Foghorn Therapeutics Inc.). Broadway Financial Corp runs the higher net margin — 1934.0% vs -234.3%, a 2168.2% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 10.1%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 9.7%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
BYFC vs FHTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $9.2M |
| Net Profit | $1.0M | $-21.7M |
| Gross Margin | — | — |
| Operating Margin | — | -258.2% |
| Net Margin | 1934.0% | -234.3% |
| Revenue YoY | 10.1% | 223.8% |
| Net Profit YoY | -21.8% | -11.1% |
| EPS (diluted) | $0.02 | $-0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $9.2M | ||
| Q3 25 | $9.0M | $8.2M | ||
| Q2 25 | $8.1M | $7.6M | ||
| Q1 25 | $8.3M | $6.0M | ||
| Q4 24 | $8.6M | $2.9M | ||
| Q3 24 | $8.7M | $7.8M | ||
| Q2 24 | $8.2M | $6.9M | ||
| Q1 24 | $7.8M | $5.0M |
| Q4 25 | $1.0M | $-21.7M | ||
| Q3 25 | $-23.9M | $-15.8M | ||
| Q2 25 | $752.0K | $-17.9M | ||
| Q1 25 | $-2.7M | $-18.8M | ||
| Q4 24 | $1.3M | $-19.5M | ||
| Q3 24 | $516.0K | $-19.1M | ||
| Q2 24 | $256.0K | $-23.0M | ||
| Q1 24 | $-154.0K | $-25.0M |
| Q4 25 | — | -258.2% | ||
| Q3 25 | -256.2% | -226.9% | ||
| Q2 25 | 12.8% | -279.2% | ||
| Q1 25 | -45.3% | -385.0% | ||
| Q4 24 | 21.7% | -840.5% | ||
| Q3 24 | 8.5% | -305.5% | ||
| Q2 24 | 4.8% | -386.6% | ||
| Q1 24 | -2.9% | -558.3% |
| Q4 25 | 1934.0% | -234.3% | ||
| Q3 25 | -264.2% | -194.4% | ||
| Q2 25 | 9.3% | -237.3% | ||
| Q1 25 | -32.3% | -316.4% | ||
| Q4 24 | 15.3% | -682.9% | ||
| Q3 24 | 5.9% | -244.9% | ||
| Q2 24 | 3.1% | -333.6% | ||
| Q1 24 | -2.0% | -495.4% |
| Q4 25 | $0.02 | $-0.35 | ||
| Q3 25 | $-2.86 | $-0.25 | ||
| Q2 25 | $0.00 | $-0.28 | ||
| Q1 25 | $-0.39 | $-0.30 | ||
| Q4 24 | $0.07 | $-0.23 | ||
| Q3 24 | $-0.03 | $-0.31 | ||
| Q2 24 | $0.02 | $-0.45 | ||
| Q1 24 | $-0.02 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $80.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $-108.5M |
| Total Assets | $1.3B | $198.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $80.9M | ||
| Q3 25 | $19.7M | $89.3M | ||
| Q2 25 | $29.5M | $72.6M | ||
| Q1 25 | $15.8M | $61.0M | ||
| Q4 24 | $61.4M | $55.5M | ||
| Q3 24 | $97.1M | $57.7M | ||
| Q2 24 | $89.8M | $138.9M | ||
| Q1 24 | $67.1M | $79.3M |
| Q4 25 | $262.8M | $-108.5M | ||
| Q3 25 | $261.7M | $-89.7M | ||
| Q2 25 | $284.7M | $-76.7M | ||
| Q1 25 | $283.6M | $-61.7M | ||
| Q4 24 | $285.0M | $-45.5M | ||
| Q3 24 | $286.2M | $-28.3M | ||
| Q2 24 | $282.1M | $-14.3M | ||
| Q1 24 | $281.1M | $-97.5M |
| Q4 25 | $1.3B | $198.1M | ||
| Q3 25 | $1.3B | $205.0M | ||
| Q2 25 | $1.2B | $226.2M | ||
| Q1 25 | $1.3B | $258.7M | ||
| Q4 24 | $1.3B | $284.0M | ||
| Q3 24 | $1.4B | $308.4M | ||
| Q2 24 | $1.4B | $328.6M | ||
| Q1 24 | $1.4B | $255.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-22.3M |
| Free Cash FlowOCF − Capex | $-13.0K | — |
| FCF MarginFCF / Revenue | -0.1% | — |
| Capex IntensityCapex / Revenue | 2.6% | 0.0% |
| Cash ConversionOCF / Net Profit | 0.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-22.3M | ||
| Q3 25 | $3.8M | $-18.9M | ||
| Q2 25 | $3.0M | $-21.0M | ||
| Q1 25 | $-4.3M | $-24.0M | ||
| Q4 24 | $1.4M | $-24.5M | ||
| Q3 24 | $6.1M | $-21.0M | ||
| Q2 24 | $9.8M | $-25.5M | ||
| Q1 24 | $-11.7M | $-29.3M |
| Q4 25 | $-13.0K | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $3.0M | $-21.0M | ||
| Q1 25 | $-4.4M | $-24.0M | ||
| Q4 24 | $1.3M | $-25.0M | ||
| Q3 24 | $6.1M | $-21.3M | ||
| Q2 24 | $9.7M | $-25.6M | ||
| Q1 24 | $-11.7M | $-29.4M |
| Q4 25 | -0.1% | — | ||
| Q3 25 | 41.1% | — | ||
| Q2 25 | 37.0% | -278.2% | ||
| Q1 25 | -52.4% | -403.2% | ||
| Q4 24 | 14.7% | -875.3% | ||
| Q3 24 | 69.6% | -273.0% | ||
| Q2 24 | 118.9% | -371.0% | ||
| Q1 24 | -149.7% | -583.1% |
| Q4 25 | 2.6% | 0.0% | ||
| Q3 25 | 1.2% | 0.0% | ||
| Q2 25 | 0.2% | 0.3% | ||
| Q1 25 | 0.2% | 0.5% | ||
| Q4 24 | 1.6% | 16.8% | ||
| Q3 24 | 0.3% | 4.0% | ||
| Q2 24 | 0.5% | 0.2% | ||
| Q1 24 | 0.7% | 2.0% |
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
